Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease

Journal of the American College of Cardiology

Volumn 43, Issue 9, 2004, Pages 1565-1573

  Yousufuddin, Mohammed ^a   Cook, Daniel J ^a   Starling, Randall C ^a   Abdo, Ashraf ^a   Paul, Philip ^a   Tuzcu, E Murat ^a   Ratliff, Norman B ^a   McCarthy, Patrick M ^a   Young, James B ^a   Yamani, Mohamad H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

ACE; Ang II; angiotensin II; angiotensin II type 1 receptor; angiotensin II type 2 receptor; angiotensin converting enzyme; AT1R; AT2R; changes in maximal intimal thickness; changes in plaque volume; CMIT; CPV; HBSS

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; MESSENGER RNA;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; EVALUATION; FEMALE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; INTRAVASCULAR ULTRASOUND; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RECIPIENT; SPLEEN;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DISEASE PROGRESSION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RISK FACTORS; RNA, MESSENGER; TISSUE DONORS; TREATMENT OUTCOME; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 2342436624     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.11.060     Document Type: Article

References (36)

1. Behrendt D., Ganz P., Fang J.C. Cardiac allograft vasculopathy. Curr Opin Cardiol. 15:2000;422-429
2. Billingham M. Histopathology of graft coronary disease. J Heart Lung Transplant. 3:1992;538-544
3. Costanzo M.R., Naftel D., Pritzker M., et al. Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. Cardiac transplant research database. J Heart Lung Transplant. 17:1998;744-753
4. Yeung A.C., Davis S.F., Hauptman P.J., et al. Incidence and progression of transplant coronary artery disease over 1 year: results from a multicenter trial with use of intravascular ultrasound: Multicenter Intravascular Ultrasound Transplant Study Group. J Heart Lung Transplant. 14:1995;S215-S220
5. Kaye M. The registry of the International Society for Heart and Lung Transplantation: tenth official report - 1993. J Heart Lung Transplant. 12:1993;541-548
6. Kobashigawa J. Coronary artery disease in the transplanted heart: why does it happen and what can we do about it? Cardiol Rev. 4:1996;1-11
7. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque stability. Circulation. 101:2000;1372-1378
8. Zachary A, Teresi G. Isolation of lymphocyte from lymph nodes and spleen. In: Lefor W, editor. ASHI Laboratory Manual, 2nd edition. Lenexa, KS: American Society of Histocompatibility and Immunogenetics, 1990:32-7.
9. Billingham M.E., Cary N.R., Hammond M.E., et al. Heart rejection study group. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. The International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 9:1990;587-593
10. -CT method. Methods. 25:2001;402-408
11. Tuzcu E., Hobbs R., Rincon G., et al. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation. Circulation. 91:1995;1706-1713
12. Principal Investigators of CASS and their Associates. National Heart, Lung, and Blood Institute Coronary Artery Surgery Study A multicenter comparison of the effects of randomized medical treatement of mildly symptomatic patients with coronary artery disease, and registry of consecutive patients undergoing coronary angiography. Circulation. 63:(Suppl I):1981;I14-I59
13. Hanley J., McNeil B. The meaning and use of area under a receiver operating characteristic (ROC) curve. Radiology. 143:1982;29-36
14. Yamani M.H., Haji S., Starling R.C., et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol. 39:2002;978-980
15. 2 receptors in the normal and failing human heart. J Pharmacol Exp Ther. 284:1998;323-336
16. Nataraj C., Oliverio M., Mannon R., et al. Angiotensin II regulates cellular immune response through a calcineurin-dependent pathway. J Clin Invest. 104:1999;1693-1701
17. Paul L., Davidoff A., Benediktsson H. Cardiac allograft atherosclerosis in the rat. The effect of histocompatibility factors, cyclosporine, and an angiotensin-converting enzyme inhibitor. Transplantation. 57:1994;1767-1772
18. Mehra M.R., Ventura H.O., Smart F.W., Collins T., Ramee S., Stapleton D. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol. 75:1995;853-854
19. Cunningham D., Crisp S., Barbir M., Lazem F., Dunn M., Yacoub M. Donor ACE gene polymorphism: a genetic risk factor for accelerated coronary sclerosis following cardiac transplantation. Eur Heart J. 19:1998;319-325
20. Pethig K., Heublein B., Hoffman A., Borlak J., Wahlers T., Haverich A. ACE gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients. J Heart Lung Transplant. 19:2000;1175-1182
21. Jorde U., Ennezat P., Lisker J., et al. Maximally recommended doses of angiotensin-converting enzyme inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 101:2000;844-846
22. McMurray J.V., Ostergren J., Swedberg K., Granger B., et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet. 362:2003;767-771
23. Pethig K., Klauss V., Heublein B., et al. Progression of cardiac allograft vascular disease as assessed by serial intravascular ultrasound: correlation to immunological and non-immunological risk factors. Heart. 84:2000;494-498
24. Mehra M.R., Ventura H.O., Stapleton D., et al. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant. 14:1995;632-639
25. Ruiz-Ortega M., Lorenzo O., Ruperez M., et al. Role of renin-angiotensin system in vascular disease. Hypertension. 38:2001;1382-1391
26. Nickenig G., Strehlow K., Roeling J., Zolk O., Knorr A., Bohm M. Salt induces vascular AT1 receptor overexpression in vitro and in vivo. Hypertension. 31:1998;1272-1277
27. Yamada T., Akishita M., Pollman M.J., Gibbons G.H., Dzau V.J., Horiuchi M. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin type 1 receptor action: an in vitro gene transfer study. Life Sci. 63:1998;L289-L295
28. Gao S., Schroeder J.S., Alderman E.L., et al. Prevalence of accelerated coronary artery disease in heart transplant survivors: comparison of cyclosporine and azathioprine regimens. Circulation. 80:1989;III100-III105
29. Gao S., Schroeder J., Hunt S., Valentine H., Hill I., Stinson E. Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis. J Heart Lung Transplant. 12:1993;1029-1035
30. Costanzo-Nordin M. Cardiac allograft vasculopathy: relationship withacute cellular rejection and histocompatibility. J Heart Lung Transplant. 11:1992;S90-104
31. Klahr S., Morrissey J. Angiotensin II and gene expression in kidney. Am J Kidney Dis. 31:1998;171-176
32. Shimada K., Yazaki Y. Binding sites for angiotensin II in human mononuclear leukocytes. J Biomech. 84:1978;1013-1015
33. Tsutsumi K., Stromberg C., Saavedra J. Characterization of angiotensin II receptor subtypes in the rat spleen. Peptides. 13:1992;291-296
34. Hisada Y., Sugaya T., Yamanouchi M., et al. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest. 103:1999;627-635
35. Muller D., Shagdarsuren E., Park J., et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol. 161:2002;1679-1693
36. Mackenzie H., Ziai F., Nagano H., et al. Candesartan cilexetil reduces chronic renal allograft injury in Fisher-Lewis rats. J Hypertens Suppl. 15:1997;S21-S25